CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 12 target
Drug / intervention
Panitumumab-IRDye800 +3 moredrug
Likely dose
Not stated in record
Key inclusion· 6
  • Suspected brain tumors undergoing surgical removal as standard of care
  • May include subjects status post chemotherapy and/or radiation or diagnostic biopsy candidates for resection
  • Eligible for resection as determined by operating surgeon
  • Planned standard of care surgery
Key exclusion· 8
  • Investigational drug within 30 days prior to first dose
  • Myocardial infarction, cerebrovascular accident, uncontrolled CHF, significant liver disease, or unstable angina within 6 months
  • History of infusion reactions to monoclonal antibody therapies
  • Pregnant or breastfeeding

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04085887
NCT04085887Phase 2RecruitingOn Track

Phase 1/Phase 2, Open Label Study Evaluating the Safety, Dosing and Efficacy of Panitumumab IRDye800 as an Optical Imaging Agent to Detect Pediatric Neoplasms During Neurosurgical Procedures

Stanford University·interventional·Posted Sep 11, 2019·Updated Jun 30, 2026

In Brief

A Phase 2 clinical trial evaluating Panitumumab-IRDye800, Pinpoint-IR9000 endoscopic/handheld device, and 2 other interventions for Brain Tumor. Currently recruiting, targeting 12 participants across 1 site.

Detailed Summary

The objective of the study is to assess safety of panitumumab-IRDye800 in pediatric patients undergoing brain surgery to remove suspected tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Tumor
CountriesUnited States
Collaborators--

Timeline

Phase 2Recruiting
2020202120222023202420252026202720282029
First PostedSep 11, 2019
Enrollment StartAug 1, 2026
Primary CompletionDec 1, 2028
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.8 years agoPrimary completion in 2.4 years

Interventions

Panitumumab-IRDye800drug

Panitumumab-IRDye800 is an imaging agent prepared as a drug-dye compound from panitumumab (Vectibix), a fully-humanized IgG2 monoclonal anti-epidermal growth factor receptor (EGFR) antibody, and IRDye800CW dye. Panitumumab-IRDye800 delivered intravenous (IV).

Pinpoint-IR9000 endoscopic/handheld devicedevice

Novadaq intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the "back table" in the surgery suite (ex-vivo).

Explorer Air cameradevice

Surgvision intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the "back table" in the surgery suite (ex-vivo).

PDE-NEO-IIdevice

Hamamatsu Photonics KK intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the "back table" in the surgery suite (ex-vivo).